Le Lézard
Classified in: Health, Science and technology
Subject: OFR

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes


WALTHAM, Mass., Oct. 19, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") announced today that it has priced an offering of $5.85 billion aggregate principal amount (the "Offering") of the following notes, each issued at par:

The Offering is expected to close on or about October 22, 2021, subject to customary closing conditions. The Floating Rate Notes will pay interest quarterly. The Fixed Rate Notes will pay interest on a semi-annual basis.

Thermo Fisher intends to use the net proceeds of the Offering to pay a portion of the cash consideration payable for the proposed acquisition of PPD, Inc., a Delaware corporation. Thermo Fisher may also determine to use a portion of the net proceeds of the Offering for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures or the repurchase of its outstanding equity securities or it may temporarily invest the net proceeds in short-term, liquid investments until they are used for their ultimate purpose.

The joint book-running managers for the Offering are Barclays Capital Inc., Morgan Stanley & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc. and Mizuho Securities USA LLC.

The Offering is being made pursuant to an effective registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (the "SEC"). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the Offering and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and this Offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any dealer participating in the Offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. toll-free at 1-888-603-5847; Morgan Stanley & Co. LLC toll-free at 1-866-718-1649; BofA Securities, Inc. toll-free at 1-800-294-1322; Citigroup Global Markets Inc. toll-free at 1-800-831-9146; or Mizuho Securities USA LLC toll-free at 1-866-271-7403.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Thermo Fisher's intended use of proceeds. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions, the pending acquisition of PPD, and completion of the Offering. Additional important factors and information regarding Thermo Fisher's business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the prospectus and prospectus supplement dated October 19, 2021 related to the Offering, which is on file with the SEC and available in the "Investors" section of our website under the heading "SEC Filings," and the documents incorporated by reference into the prospectus and prospectus supplement. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Thermo Fisher Scientific logo (PRNewsfoto/Thermo Fisher Scientific)

Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com 

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

SOURCE Thermo Fisher Scientific


These press releases may also interest you

at 00:00
Trails Carolina, the leader in wilderness therapy for pre-teens and teens, teamed up with the Arkansas Institute of Developmental Science and the Center for Research, Assessment, and Treatment Efficacy to assess the impacts on youth and their...

26 nov 2021
Public Health Agency of Canada The Government of Canada is working with partners to protect the health and safety of Canadians and Temporary Foreign Workers in Canada, and to reduce the spread of COVID-19 and its variants in Canada. Self-isolation is...

26 nov 2021
Public health authorities in South Africa have confirmed that a new COVID-19 variant of concern (B.1.1.529) has been detected in that country. Over the past 24 hours, this variant ? named Omicron by the World Health Organization ? has also been...

26 nov 2021
CARESPAN HEALTH, INC. (formerly Dynamo Capital Corp.) ("CareSpan" or the "Company") is pleased to announce that, subject to the approval of the TSX Venture Exchange (the "TSX-V"), it has engaged the services of Generation IACP Inc. ("Generation") to...

26 nov 2021
Cybin Inc. (NEO:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing "Psychedelics to Therapeuticstm", is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved...

26 nov 2021
Asclepius Meditec ("the Company"), the organizer of the conference, is pleased to announce that five academicians of the Chinese Academy of Engineering, Zhong Nanshan, Tang Zhaoyou, Fan Daiming, Xia Zhaofan and Ding Wenjiang, will deliver important...



News published on 19 october 2021 at 20:36 and distributed by: